Investor Relations

Financial Releases

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Reports Second Quarter 2015 Results
Revenue Increased 77% Year Over Year to $15.2 Million and Gross Margins Rise to 81% MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT , Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for
View HTML
Toggle Summary Intersect ENT to Present at the Wedbush PacGrow Life Sciences and Canaccord Genuity Conferences
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq: XENT) today announced that management will present an overview of the company's business at the Wedbush PacGrow Life Sciences 2015 Life Sciences Management Access Conference and at the Canaccord Genuity 2015 Growth Conference.
View HTML
Toggle Summary Intersect ENT to Announce Second Quarter Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release its second quarter financial results on August 5, 2015 .
View HTML
Toggle Summary Intersect ENT to Present at Cantor Fitzgerald's Inaugural Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that management will present an overview of the company's business at Cantor Fitzgerald's Healthcare
View HTML
Toggle Summary Intersect ENT Announces Exercise of Underwriters' Option and the Closing of Its Public Offering
Underwriters Exercise Option for 537,300 Shares of Common Stock, Increasing Total Aggregate Proceeds to Approximately $103.0 Million MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT , Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and
View HTML
Toggle Summary Intersect ENT to Present at the William Blair & Company 35th Annual Growth Stock Conference
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that management will present an overview of the company's business at the William Blair & Company 35 th
View HTML
Toggle Summary Intersect ENT Announces Upsizing and Pricing of Public Offering
Public Offering of 3,582,000 Shares of Common Stock at $25.00 per Share, Resulting in Aggregate Proceeds of Approximately $89.6 Million MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT , Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and
View HTML
Toggle Summary Intersect ENT Commences Public Offering
Public Offering of 3,000,000 Shares of Common Stock MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT , Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the commencement of an underwritten public offering
View HTML
Toggle Summary Intersect ENT Files S-1 Registration Statement for Proposed Public Offering
Proposed Public Offering of 3,000,000 Shares of Common Stock MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT , Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today filed a registration statement on Form S-1 with the
View HTML
Toggle Summary Intersect ENT Reports First Quarter 2015 Results
Revenue Increased 78% Year Over Year to $13.4 Million MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT , Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the first quarter ended March
View HTML